Data temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 0/5 criteria met.
- ❌ Price trend failed
- ⚠️ Mixed growth
- ❌ Debt failed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2018 → 2019: 1.73%
Price change 2019 → 2020: -77.38%
Price change 2020 → 2021: 8.12%
Price change 2021 → 2022: -8.06%
Price change 2022 → 2023: -10.79%
Price change 2023 → 2024: 0.00%
Price change 2024 → 2025: 48.87%
Price change 2025 → 2026: 79.13%
Price change 2026 (year to date): 79.81%
Financial growth
Revenue CAGR (8 years): 166.24%
Earnings CAGR (8 years): N/A
Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.
Debt
Debt-to-equity ratio: 150685000.00
Debt/equity > 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -5.19
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 35.61% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Genfit S.A. | – | – | +21.0 % | 🔒 |
| Valneva SE | – | 1.95 | +22.4 % | – |
| Lumibird S.A. | 37.3 | 0.71 | +9.8 % | – |
| Transgene S.A. | – | 0.02 | −20.1 % | – |
| Clariane SE | 565.5 | 2.16 | +12.4 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|